J&J's carisbamate shows mixed efficacy in epilepsy in Phase III
This article was originally published in Scrip
Johnson & Johnson's anti-epileptic candidate, carisbamate, has shown mixed efficacy as an adjunctive treatment of partial onset seizures in Phase III data that were presented at the recent American Epilepsy Society meeting.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.